The growth in the historic period can be attributed to high global hepatitis c prevalence, early reliance on interferon therapies, lack of alternative antivirals, hospital based antiviral treatment, clinical familiarity with interferons.
The growth in the forecast period can be attributed to shift toward direct acting antivirals, niche demand in resistant cases, improved hepatitis screening programs, liver disease management focus, declining interferon dependency. Major trends in the forecast period include declining use of interferon based therapies, selective use in treatment resistant patients, combination therapy optimization, focus on viral load suppression, monitoring of long term liver outcomes.
The increasing prevalence of chronic hepatitis C is projected to propel the growth of the infergen market in the future. Chronic hepatitis C is a long-term infection caused by the hepatitis C virus, where the virus persists in the body for over six months. If untreated, it can lead to severe health complications like liver damage, cirrhosis, and liver cancer. The rise in chronic hepatitis C cases is mainly attributed to higher rates of injection drug use, which enables blood-to-blood transmission of the virus, as well as limited access to prevention and treatment services. Infergen, a pegylated version of interferon alfa-2b, aids patients with chronic hepatitis C by stimulating the immune system to combat the virus. This process helps improve liver function, lower viral load, and potentially achieve a sustained virologic response (SVR), which is essential in preventing liver damage and related complications. For example, in April 2025, the European Centre for Disease Prevention and Control (ECDC) reported that 28,622 cases of hepatitis C were identified in 29 EU/EEA countries in 2023, with a crude rate of 7.4 cases per 100,000 people. Of the reported cases, 4.9% were acute, 34.1% chronic, and 53.8% unknown. As a result, the rising number of chronic hepatitis C cases is driving the growth of the infergen market.
The growing demand for personalized medicine is expected to significantly accelerate the growth of the infergen market. Personalized medicine involves tailoring medical treatments to suit the specific characteristics, needs, and preferences of each patient, often based on their genetic makeup. It aims to improve treatment effectiveness while reducing adverse effects by considering individual variations in genetics, environment, and lifestyle. The increasing demand for personalized medicine is driven by patients seeking more effective healthcare solutions that are customized to their unique genetic, physiological, and lifestyle factors. Infergen (interferon alfacon-1) is used in personalized medicine by adapting treatment regimens to individual factors, such as viral load and genotype, in chronic hepatitis C patients. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization representing scientists, patients, and providers, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, a rise from six approvals in 2022. Therefore, the growing demand for personalized medicine is expected to contribute to the expansion of the infergen market.
The global expansion of healthcare infrastructure is expected to significantly accelerate the growth of infergen in the coming years. Healthcare infrastructure encompasses the physical and organizational structures, resources, facilities, and systems required to deliver healthcare services to a population. This global expansion is fueled by factors such as an aging population, increasing chronic diseases, and technological advancements. Healthcare infrastructure supports the use of infergen by providing essential medical facilities, skilled professionals, diagnostic tools, and treatment protocols, all of which are necessary for the effective administration of the drug, monitoring patient progress, and managing potential side effects, thus ensuring optimal results for chronic hepatitis C patients. For instance, in April 2025, the Office for National Statistics, a UK government agency, reported that healthcare spending in the UK reached approximately US$414 billion (£317 billion) in 2024. Moreover, healthcare expenditure grew by 6.5% in nominal terms from 2023 to 2024. Consequently, the global expansion of healthcare infrastructure is driving the growth of the infergen market.
Major companies operating in the infergen market are Amgen Inc.
North America was the largest region in the infergen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infergen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infergen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the infergen market by increasing costs associated with recombinant protein manufacturing inputs and sterile injectable packaging. Hospital and specialty clinic segments in north america and parts of europe are most affected due to import reliance. These tariffs may limit broader usage and favor alternative therapies. At the same time, tariffs are encouraging localized biologics production and improving regional self sufficiency for antiviral injectables.
The infergen market research report is one of a series of new reports that provides infergen market statistics, including infergen industry global market size, regional shares, competitors with a infergen market share, detailed infergen market segments, market trends and opportunities, and any further data you may need to thrive in the infergen industry. This infergen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Infergen (Interferon alfacon-1) is a recombinant type-I interferon primarily used for treating chronic hepatitis C virus infection in adults with compensated liver disease. It is a synthetic version of interferon, produced using genetically modified Escherichia coli bacteria, designed to replicate the natural interferons found in the human body.
The main patient demographics for Infergen include pediatric patients, adult patients, and high-risk groups. Pediatric patients, typically under 18 years of age, are treated with Infergen for chronic hepatitis C, where it helps stimulate the immune system to combat the virus and reduce liver damage. Infergen is utilized in combination therapy for chronic hepatitis C treatment and is distributed through various channels such as hospitals, specialty clinics, online pharmacies, and retail pharmacies.
The infergen market includes sales of interferon alfacon-1 injection products available in single-use vials containing 9 mcg and 15 mcg formulations, and combination therapy kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to shift toward direct acting antivirals, niche demand in resistant cases, improved hepatitis screening programs, liver disease management focus, declining interferon dependency. Major trends in the forecast period include declining use of interferon based therapies, selective use in treatment resistant patients, combination therapy optimization, focus on viral load suppression, monitoring of long term liver outcomes.
The increasing prevalence of chronic hepatitis C is projected to propel the growth of the infergen market in the future. Chronic hepatitis C is a long-term infection caused by the hepatitis C virus, where the virus persists in the body for over six months. If untreated, it can lead to severe health complications like liver damage, cirrhosis, and liver cancer. The rise in chronic hepatitis C cases is mainly attributed to higher rates of injection drug use, which enables blood-to-blood transmission of the virus, as well as limited access to prevention and treatment services. Infergen, a pegylated version of interferon alfa-2b, aids patients with chronic hepatitis C by stimulating the immune system to combat the virus. This process helps improve liver function, lower viral load, and potentially achieve a sustained virologic response (SVR), which is essential in preventing liver damage and related complications. For example, in April 2025, the European Centre for Disease Prevention and Control (ECDC) reported that 28,622 cases of hepatitis C were identified in 29 EU/EEA countries in 2023, with a crude rate of 7.4 cases per 100,000 people. Of the reported cases, 4.9% were acute, 34.1% chronic, and 53.8% unknown. As a result, the rising number of chronic hepatitis C cases is driving the growth of the infergen market.
The growing demand for personalized medicine is expected to significantly accelerate the growth of the infergen market. Personalized medicine involves tailoring medical treatments to suit the specific characteristics, needs, and preferences of each patient, often based on their genetic makeup. It aims to improve treatment effectiveness while reducing adverse effects by considering individual variations in genetics, environment, and lifestyle. The increasing demand for personalized medicine is driven by patients seeking more effective healthcare solutions that are customized to their unique genetic, physiological, and lifestyle factors. Infergen (interferon alfacon-1) is used in personalized medicine by adapting treatment regimens to individual factors, such as viral load and genotype, in chronic hepatitis C patients. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization representing scientists, patients, and providers, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, a rise from six approvals in 2022. Therefore, the growing demand for personalized medicine is expected to contribute to the expansion of the infergen market.
The global expansion of healthcare infrastructure is expected to significantly accelerate the growth of infergen in the coming years. Healthcare infrastructure encompasses the physical and organizational structures, resources, facilities, and systems required to deliver healthcare services to a population. This global expansion is fueled by factors such as an aging population, increasing chronic diseases, and technological advancements. Healthcare infrastructure supports the use of infergen by providing essential medical facilities, skilled professionals, diagnostic tools, and treatment protocols, all of which are necessary for the effective administration of the drug, monitoring patient progress, and managing potential side effects, thus ensuring optimal results for chronic hepatitis C patients. For instance, in April 2025, the Office for National Statistics, a UK government agency, reported that healthcare spending in the UK reached approximately US$414 billion (£317 billion) in 2024. Moreover, healthcare expenditure grew by 6.5% in nominal terms from 2023 to 2024. Consequently, the global expansion of healthcare infrastructure is driving the growth of the infergen market.
Major companies operating in the infergen market are Amgen Inc.
North America was the largest region in the infergen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infergen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infergen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the infergen market by increasing costs associated with recombinant protein manufacturing inputs and sterile injectable packaging. Hospital and specialty clinic segments in north america and parts of europe are most affected due to import reliance. These tariffs may limit broader usage and favor alternative therapies. At the same time, tariffs are encouraging localized biologics production and improving regional self sufficiency for antiviral injectables.
The infergen market research report is one of a series of new reports that provides infergen market statistics, including infergen industry global market size, regional shares, competitors with a infergen market share, detailed infergen market segments, market trends and opportunities, and any further data you may need to thrive in the infergen industry. This infergen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Infergen (Interferon alfacon-1) is a recombinant type-I interferon primarily used for treating chronic hepatitis C virus infection in adults with compensated liver disease. It is a synthetic version of interferon, produced using genetically modified Escherichia coli bacteria, designed to replicate the natural interferons found in the human body.
The main patient demographics for Infergen include pediatric patients, adult patients, and high-risk groups. Pediatric patients, typically under 18 years of age, are treated with Infergen for chronic hepatitis C, where it helps stimulate the immune system to combat the virus and reduce liver damage. Infergen is utilized in combination therapy for chronic hepatitis C treatment and is distributed through various channels such as hospitals, specialty clinics, online pharmacies, and retail pharmacies.
The infergen market includes sales of interferon alfacon-1 injection products available in single-use vials containing 9 mcg and 15 mcg formulations, and combination therapy kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Infergen Market Characteristics
3. Infergen Market Supply Chain Analysis
4. Global Infergen Market Trends and Strategies
5. Infergen Market Analysis of End Use Industries
7. Global Infergen Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Infergen Total Addressable Market (TAM) Analysis for the Market
9. Infergen Market Segmentation
10. Infergen Market Regional and Country Analysis
11. Asia-Pacific Infergen Market
12. China Infergen Market
13. India Infergen Market
14. Japan Infergen Market
15. Australia Infergen Market
16. South Korea Infergen Market
17. Western Europe Infergen Market
18. UK Infergen Market
19. Germany Infergen Market
20. France Infergen Market
21. Eastern Europe Infergen Market
22. North America Infergen Market
23. USA Infergen Market
24. Canada Infergen Market
25. South America Infergen Market
26. Middle East Infergen Market
27. Africa Infergen Market
29. Infergen Market Competitive Landscape and Company Profiles
32. Infergen Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Infergen Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses infergen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for infergen? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The infergen market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Patient Demographics: Pediatric Patients; Adult Patients; High-Risk Groups2) By Application: Chronic Hepatitis C Treatment; Combination Therapy
3) By Distribution Channel: Hospitals; Specialty Clinics; Online Pharmacies; Pharmacies
Companies Mentioned: Amgen Inc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Infergen market report include:- Amgen Inc.
